Most states pass on Trump’s discounted GLP-1 deal, tightening Medicaid access

Trump’s plan to negotiate discounted GLP-1 weight‑loss drugs for Medicaid has stalled: only Indiana has signed on, while 29 states will not participate due to tight budgets. Twelve states still cover GLP-1s, but five of those recently ended coverage (California, Massachusetts, New Hampshire, Pennsylvania and South Carolina), with Rhode Island set to end in October. As other states weigh participation, many cite cost concerns and the risk to budget sustainability, meaning access to these drugs for low-income Americans on Medicaid is shrinking even as some argue these medications could reduce long-term health costs.